Attapon Cheepsattayakorn^1,2*, Ruangrong Cheepsattayakorn³ and Porntep Siriwanarangsun¹

¹Faculty of Medicine, Western University, Pathumtani Province, Thailand
²10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand
³Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

*Corresponding Author: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.

Received: May 29, 2023; Published: October 01, 2023

Abstract

Even after triple COVID-19 vaccination, several populationbased studies have demonstrated that patients with cancer continue to be at an increase risk of COVID-19 infections, depending on specific cancer types and different active therapies [1]. Higher cumulative risk was identified in vaccinated patients with lung, colorectal, liver, and pancreatic cancer, whereas lower risk was seen in vaccinated patients with prostate, breast, and gynecological cancer [1]. Data from several retrospective studies confirmed the improvement the short-term clinical outcomes by decreasing hospitalization and 30-day mortality among patients with cancer [2,3].

References

1. Lee LYW., et al. “UK Coronavirus Cancer Programme. COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalizations and death in patients with cancer : a population-based study”. European Journal of Cancer 175 (2022): 1-10.
2. Choueiri TK., et al. “Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines : a retrospective observation study from the COVID-19 and Cancer Consortium”. The Lancet Regional Health 19 (2023): 100445.
3. Gong IY., et al. “Association of COVID-19 vaccination with breakthrough infections and complications in patients with cancer”. JAMA Oncology 9 (2023): 386-394.
4. van Vliet ED., et al. “Physical and mental health outcomes of COVID-19 induced delay in oncological care : a systematic review”. Frontiers in Oncology 13 (2023): 998940.
5. Booth S., et al. “Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy”. British Journal of Haematology 196 (2022): 892-901.
6. Nelli F., et al. “Effects of antibody response after booster vaccination on SARS-CoV-2 breakthrough infections and disease outcomes in advanced cancer patients : a prospective analysis of the Vax-on-Third Study”. Current Oncology 30 (2023): 5103-5115.

Citation

Citation: Attapon Cheepsattayakorn., et al. “Advanced Cancer Patients with SARS-CoV-2 Breakthrough Infections with Antibody Response After Booster Vaccination". Acta Scientific Microbiology 6.11 (2023): 01-02.

Copyright

Copyright: © 2023 Attapon Cheepsattayakorn., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.